Shares of Virpax Pharmaceuticals Inc. (VRPX) Exceed 52-Week High

July 7, 2021 11:14:23

Shares of Virpax Pharmaceuticals Inc. (NASDAQ:VRPX) traded today at $8.48, eclipsing its 52-week high. Approximately 3.3 million shares have changed hands today, as compared to an average 30-day volume of 627,000 shares.

Based on a current price of $5.77, Virpax Pharmaceuticals Inc. is currently 51.8% above its average consensus analyst price target of $2.78.

Over the past year, Virpax Pharmaceuticals Inc. has traded in a range of $3.70 to $8.48 and is now at $5.77, 56% above that low.

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected

About InvestorBrandNetwork (IBN)
InvestorBrandNetwork (IBN) consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign.

For more information, please visit https://www.InvestorBrandNetwork.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer